| Document |
Document Title |
|
WO/2005/030704A1 |
The invention relates to the inhibition of histone deacetylase. The invention provides compounds and methods for inhibiting histone deacetylase enzymatic activity. The invention also provides compositions and methods for treating cell pr...
|
|
WO/2005/030694A1 |
The invention features 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs, compositions containing them, and methods of using them as PPAR delta modulators to treat or inhibit the progression of, for example, dyslipidemia.
|
|
WO/2005/030746A1 |
Novel calcilytic compounds and methods of using them are provided.
|
|
WO/2005/028429A2 |
The application is directed to haloalkyl-substituted compounds of formula (I) wherein R7 represents haloalkyl; and R1, R2, R3, R4, R5, R6 and R8 are as defined in the claims. The compounds are inhibitors of cysteine proteases, in particu...
|
|
WO/2005/028426A1 |
A compound of the present invention and pharmaceutically acceptable salts thereof are represented by the following general formula (1). (1) (In the formula (1), the definitions of R1, R2, R3, R4, R5, R6, Q, R8 and R9 are the same as thos...
|
|
WO/2005/028430A1 |
The present invention is concerned with an improved process for the preparation of the selective serotonin reuptake inhibitor 3-[(Dimethylamino)methyl]-4-[4-(methylsulfanyl)phenoxy]benze
nesulfonamide (L) or (D) tartrate (I) and with int...
|
|
WO/2005/026110A1 |
A useful novel intermediate and a novel synthesis method which enable an optically active (R)- or (S)-2-amino-3-mercapto-2-methylpropionic acid derivative or a salt thereof which each is useful as an intermediate for medicines, etc. to b...
|
|
WO/2005/025557A1 |
The present invention provides methods and compounds useful in the treatment of conditions such as metastatic cancer spread and atherosclerosis using oxamflatin and derivatives thereof. It has been found that oxamflatin and derivatives t...
|
|
WO/2005/023844A1 |
A compound useful as, e.g., a surface modifier for use in producing, e.g., a drug carrier, or a salt of the compound; and fine particles containing either of these. The compound is one obtained by modifying a substance to be modified whi...
|
|
WO/2005/022213A1 |
An optical filter which is excellent in light resistance, heat resistance, etc., does not show high absorption in the visible region, and has the ability to absorb near infrared rays. The optical filter is characterized by containing a c...
|
|
WO/2005/020897A2 |
Provided are small-molecule Trp-p8 modulators, including Trp-p8 agonists and Trp-p8 antagonists, and compositions comprising small-molecule Trp-p8 agonists as well as methods for identifying and characterizing novel small-molecule Trp-p8...
|
|
WO/2005/021493A2 |
The invention relates to a method of isolating a thiol R'SH from a thiol containing mixture. The method includes the steps of forming a mixed disulphide R'SSR of the thiol R'SH, purifying the mixed disulphide R'SSR and reducing the purif...
|
|
WO/2005/021487A1 |
This invention relates to a novel class of compounds, represented by the formula (I) below, wherein the meanings of R1, R2, R3 and R4 are indicated therein, which are cysteine protease inhibitors, including but not limited to, inhibitors...
|
|
WO/2005/019151A1 |
The present invention is directed to a compound of formula I, or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof, which is useful in treating or preventing disorders mediated by a peroxisome proliferator acti...
|
|
WO/2005/019165A1 |
The Amadori compounds of cysteine of Formula (I) in which R is hydrogen when n=1-4, or methyl when n=0-3. The compounds are useful for conferring meaty tastes and aromas on foodstuffs.
|
|
WO/2005/018529A2 |
The invention relates to certain 2-substituted phenoxyacetic acid derivatives of formula (I), in which the variables are as defined in the claims, useful in the treatment of diseases or conditions in which modulation of the CRTh2 recepto...
|
|
WO/2005/018628A1 |
Agents useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis are disclosed. Formula (I), where...
|
|
WO/2005/016862A1 |
A compound represented by the formula (I)[In the formula, Link represents a saturated or unsaturated straight hydrocarbon chain having 1 to 3 carbon atoms, C2 to C6 in the aromatic ring (E) independently represent a ring-constituting car...
|
|
WO/2005/014524A2 |
The invention provides novel polyamine and amino thiol compounds and pharmaceutical compositions for administration in conjunction with cancer chemotherapy or radiation therapy. The compounds are administered locally to provide protectio...
|
|
WO/2005/014533A2 |
This invention provides aryl and heteroaryl compounds, methods of their preparation, pharmaceutical compositions comprising the compounds, and their use in treating human or animal disorders. The compounds of the invention may be antagon...
|
|
WO/2005/014531A1 |
A process for the production of N-methacryloyl-4-cyano -3-trifluoromethylaniline which comprises reacting 4-cyano-3-trifluoromethylaniline with methacrylic acid or a reactive derivative thereof in the presence of a polymerization inhibit...
|
|
WO/2005/014532A1 |
This invention provides aryl and heteroaryl compounds of Formula (I) as described herein, and methods of their preparation. Also provided are pharmaceutical compositions made with the compounds of Formula (I) and methods for making such ...
|
|
WO/2005/014535A1 |
The invention relates to derivatives of 4,4'-dithiobis-(3-aminobutane-1-sulfonates) of formula (1), of use for the treatment and prevention of primary and secondary arterial hypertension.
|
|
WO/2005/014534A1 |
This invention provides aryl and heteroaryl compounds of Formula (I) as described herein, and methods of their preparation. Also provided are pharmaceutical compositions made with the compounds of Formula (I) and methods for making such ...
|
|
WO/2005/012234A1 |
Compounds having the Formula (I) or (III) wherein R1, R2 and R3 are each independently selected from H, OH, C1-6alkyl, C1-6alkoxy, NH2, NH-(Cl-6a1kyl), N(C1-6a1kyl)(C1-6alkyl), SH, S-C1-6alkyl, NO2, CF3, OCF3, and halo; R4 is unsubstitut...
|
|
WO/2005/011664A1 |
The present invention provides optionally substituted compounds of the formula (I) or salts thereof; wherein R1 is O or S when double bonded to the ring or is OH, SH, or a protected equivalent, when single bonded to the ring, R2 is hydro...
|
|
WO/2005/009928A2 |
The present disclosure provides methods of synthesizing alkylating agents and methods of use.
|
|
WO/2005/009940A1 |
The invention provides novel compounds according to formula I relates to compounds with the general formula I said compounds being useful, e.g. in the treatment of inflammatory, ophthalmic diseases or cancer.
|
|
WO/2005/009941A1 |
The present invention relates to compounds of Formula I: I which are agonists of the M-1 muscarinic receptor.
|
|
WO/2005/009104A2 |
The present invention is directed to hepatocyte nuclear factor 4a (HNF-4a) receptor modulator compounds. This invention is also directed to pharmaceutical compositions containing such compounds as well as methods of using such compounds ...
|
|
WO/2005/007104A2 |
The invention provides the following formula (I) and uses thereof: wherein each Ak is independently selected from the group consisting of alkyl; Cy is selected from the group consisting of cycloalkyl, substituted cycloalkyl, heterocycle,...
|
|
WO/2005/007621A2 |
This invention describes compounds useful as ubiquitin ligase inhibitors. The compounds of the invention are useful as inhibitors of the biochemical pathways of organisms in which ubiquitination is involved. The invention also provides f...
|
|
WO/2005/007091A2 |
One aspect of the invention relates to HDAC inhibitors. Methods of sensitizing a cancer cell to the cytotoxic effects of radiotherapy are also provided. The invention also provides methods for treating cancer and methods for treating neu...
|
|
WO/2005/005369A1 |
The invention relates to a method for the preparation of de 1,3-diphenylprop-2-en-1-one substituted on one of the two phenyl groups by a carboxyalkyloxy group or a carboxyalkylthio group.
|
|
WO/2005/004810A2 |
N-aryl arylsulfonamide derivatives are bradykinin B1 antagonists or inverse agonists useful in the treatment or prevention of symptoms such as pain and inflammation associated with the bradykinin B1 pathway.
|
|
WO/2005/005377A1 |
ABSTRACT A process for making a medicinal vial in which a vial and a closure are moulded in parallel in respective vial and closure moulds, then the closure and vial are automatically assembled together, all in a sterile environment. An ...
|
|
WO/2005/005376A2 |
A fungicidally active compound of the formula: wherein Q is -NY-NH-,-N=N-,or X is oxygen, sulfur, sulfoxide, or sulfone; n is 0 or 1; Y is hydrogen, C1-C4 alkanoyl, C1-C6 haloalkanoyl, C1-C6 straight chain or branched alkoxycarbonyl, C1-...
|
|
WO/2005/003094A1 |
This invention relates to novel compounds useful as potassium channel modulators. More specifically the invention provides chemical compounds useful as modulators of SKCA and/or IKCA channels.
|
|
WO/2005/000242A2 |
Process for making a pharmaceutical composition, comprising: a compound of formula (1) in crystalline form together with a pharmaceutically acceptable carrier or excipient, wherein the compound of formula (1) is present in polymorphic cr...
|
|
WO/2005/000794A1 |
Compounds of formula (I) wherein R1 to R4, X and A are as defined in the claims and pharmaceutically acceptable salts and esters thereof, are disclosed. The compounds of formula (I) possess utility as tissue-selective androgen receptor m...
|
|
WO/2005/000795A2 |
This invention relates to aniline derived non-steroidal compounds that are or are believed to be modulators of androgen, glucocorticoid, mineralocorticoid, and progesterone receptors, and also to the methods for the making and use of suc...
|
|
WO/2005/000800A1 |
This invention relates to a class of compounds having the general formula (I) which are cysteine protease inhibitors, including but not limited to, inhibitors of cathepsins K, L, S and B. These compounds are useful for treating diseases ...
|
|
WO/2005/000834A1 |
The present invention provides a compound of the formula (I) wherein R is -H, or -C1-C4 alkyl; R1 is -H, -OH, -O(C1-C4 alkyl), -SO2(C1-C4 alkyl), or halo; X is -O-, -CH2-, or -C(O)-; X1 is -O- or -NR2-; R2 is -H or -CH3; Y is -S-, -CH2CH...
|
|
WO/2005/000799A1 |
A process is described for preparing polymorphic form (I) of modafinil with high yields and with low impurity content. The process comprises the steps of (a) reacting (diphenylmethyl)thioacetic acid with a C1-C5 alcohol,(b) oxidation of ...
|
|
WO/2004/113283A1 |
A tert-butylamine salt, a piperazine salt, a choline salt, a tris(hydroxymethyl)methylamine salt, a lysine salt or an adamantylamine salt of (-)-2-&lcub [2-(4-hydroxyphenyl)ethyl]thio&rcub -3-[4-(2-&lcub 4-[(methylsulfonyl)oxy]phenoxy&rc...
|
|
WO/2004/113284A1 |
A potassium salt or a sodium salt of (-)-2-&lcub [2-(4-hydroxyphenyl)ethyl]thio&rcub -3-[4-(2-&lcub 4-[(methylsulfonyl)oxy]phenoxy&rcub ethyl)phenyl]propanoic acid, processes for their preparation, their use in treating clinical conditio...
|
|
WO/2004/113270A2 |
The present invention provides a compound of formula (I) processes for preparing such compounds, their the utility in treating clinical conditions including lipid disorders (dyslipidemias) whether or not associated with insulin resistanc...
|
|
WO/2004/113282A1 |
Substituted 3-phenylpropionic acid derivatives, processes for preparing such compounds, their utility in treating clinical conditions including lipid disorders (dyslipidemias) whether or not associated with insulin resistance, methods fo...
|
|
WO/2004/113285A1 |
The present invention provides a process for the preparation of substantially racemic 2-&lcub [2-(4-hydroxyphenyl)ethyl]thio&rcub -3-[4-(2-&lcub 4-[(methylsulfonyl)oxy]phenoxy&rcub ethyl)phenyl]-propanoic acid which comprises reacting 2-...
|
|
WO/2004/113273A1 |
Compounds of formula (I), wherein A0, A1, and A2 are each independently of the others a bond or a Cl-C6alkylene bridge; A3 is a Cl-C6alkylene bridge which is unsubstituted or substituted by from one to six identical or different substitu...
|
